Medication shows modest benefit in reducing weight, improving HDL, triglyceride levels

Use of the weight-loss medication rimonabant produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels, according to a study in the February 15 issue of JAMA.

Approximately two-thirds of U.S. adults are overweight or obese, which greatly increases the risk of developing diabetes mellitus and cardiovascular disease and death from related causes. Researchers believe that besides weight loss, obesity management should target improvement in certain cardiometabolic risk factors, which include abnormal cholesterol and glucose (blood sugar) levels and excess weight around the waist, according to background information in the article. Long-term weight management remains a challenge for patients and clinicians.

F. Xavier Pi-Sunyer, M.D., of St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, and colleagues evaluated the efficacy and safety of the weight-loss medication rimonabant in conjunction with diet and exercise in promoting reductions in body weight and waist circumference, long-term weight maintenance, and reduction of cardiometabolic risk factors in obese and higher risk overweight patients. The randomized, double-blind, placebo-controlled study, conducted from August 2001 to April 2004, included 3,045 adults who were obese (body mass index 30 or greater) or overweight (body mass index greater than 27 and treated or untreated hypertension [high blood pressure] or dyslipidemia [abnormal levels of certain lipids and lipoproteins in the blood]). Patients were randomized to receive placebo, 5 mg/d of rimonabant, or 20 mg/d of rimonabant for 1 year. Rimonabant-treated patients were re-randomized to receive placebo or continued to receive the same rimonabant dose while the placebo group continued to receive placebo during year 2.

Year 1 of the study was completed by 51 percent of patients in the placebo group, 51 percent in the 5 mg of rimonabant

Contact: Elizabeth Streich
JAMA and Archives Journals

Page: 1 2

Related medicine news :

1. Medication does not appear to offer benefit for certain heart attack patients undergoing PCI
2. Medication errors affect childrens leukemia treatment
3. Medication may promote opening of arteries following stroke
4. IOM Advisory: Preventing Medication Errors News Conference on July 20
5. Medication use linked to farmers injuries
6. Medication plus oral contraceptive may improve female pattern hair loss
7. Medication reduces risk of adverse events for patients with acute coronary syndromes undergoing PCI
8. Medications that lower blood pressure linked to reduced risk of Alzheimers disease
9. Medication plus beta-blocker helps prevent shocks from implantable cardioverter defibrillator
10. Medications and cough syrups may cause cavities
11. Medication reduces risk of heart irregularities after cardiac surgery

Post Your Comments:

(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners is ... sequencing and genomics experience, as Vice President of North American Capital Sales at ... for leading the sales team in the commercialization of the HTG EdgeSeq system and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
Cached News: